Kanabidiol

Из Википедије, слободне енциклопедије
Kanabidiol
Cannabidiol Structural formula V1.svg
CBD-3D-balls.png
IUPAC ime
2-[(1R,6R)-6-izopropenil-3-metilcikloheks-2-en-1-il]-5-pentilbenzen-1,3-diol
Klinički podaci
Prodajno ime Epidiolex
Drugs.com Internacionalno ime leka
Pravni status
Pravni status
  • AU: S4 (Prescription only)
  • CA: Plan II
  • UK: Prehrambeni suplement ili POM
  • US: Plan I[1]
Farmakokinetički podaci
Bioraspoloživost 13–19% (oralno),[2] 11–45% (prosek 31%; inhalaciono)[3]
Poluvreme eliminacije 9 h[2]
Identifikatori
CAS broj 13956-29-1 ДаY
ATC kod None
PubChem CID 644019
IUPHAR/BPS 4150
ChemSpider 24593618 ДаY
UNII 19GBJ60SN5 ДаY
ChEBI CHEBI:69478 ДаY
Hemijski podaci
Formula C21H30O2
Molarna masa 314.4636
Fizički podaci
Tačka topljenja 66 °C (151 °F)
Tačka ključanja 180 °C (356 °F)
(opseg: 160–180 °C)[4]
  (verify)

Kanabidiol (CBD) je kanabinoid prisutan u kanabisu. On je glavni sastojak biljke, koji sačinjava do 40% njenog ekstrakta.[5]

On pokazuje sedativno dejstvo u testovima na životinjama.[6] Neka istraživanja, međutim, indiciraju da CBD može da poveća budnost.[7] On može da umanji brzinu uklanjanja THC-a iz tela, verovatno putem ometanja metabolizma THC-a u jetri.

Pokazano je da omanjuje konvulzije, inflamaciju, anksioznost, i mučninu, kao i da inhibira rast ćelija kancera.[8] Nedavne studije su pokazale da je kanabidiol efektivan kao atipični antipsihotik u tretmanu šizofrenije.[9] Ispitivanja su takođe pokazala da olakšava simptome distonije.[10][11]

Novembera 2007. je objavljeno da CBD redukuje rast agresivnih ljudskih ćelija raka dojke in vitro i da umanjuje njihovu invazivnost.

Vidi još[уреди]

Reference[уреди]

  1. DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml; Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance.").
  2. 2,0 2,1 Mechoulam R, Parker LA, Gallily R (2002). „Cannabidiol: an overview of some pharmacological aspects”. J Clin Pharmacol (Review). 42 (11 Suppl): 11S—19S. PMID 12412831. doi:10.1177/0091270002238789. 
  3. Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009). „Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. Phytother Res (Review). 23 (5): 597—602. PMID 18844286. doi:10.1002/ptr.2625. 
  4. McPartland JM, Russo EB (2001). „Cannabis and cannabis extracts: greater than the sum of their parts?” (PDF). Journal of Cannabis Therapeutics. 1 (3/4): 103—132. doi:10.1300/J175v01n03_08. 
  5. Grlić, Ljubiša (1962). „A comparative study on some chemical and biological characteristics of various samples of cannabis resin”. Bulletin on Narcotics. United Nations Office on Drugs and Crime (3): 37—46. 
  6. Pickens JT (1981). „Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content”. British Journal of Pharmacology. 72 (4): 649—56. PMC 2071638Слободан приступ. PMID 6269680. 
  7. Nicholson, AN; C Turner; et al. (2004). „Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults” (fee required). J Clin Psychopharmacol. 24 (3): 305—13. ISSN 0271-0749. PMID 15118485. doi:10.1097/01.jcp.0000125688.05091.8f. Приступљено 3. 5. 2007. 
  8. Mechoulam, R.; M. Peters; Murillo-Rodriguez (21. 8. 2007). „Cannabidiol - recent advances”. Chemistry & Biodiversity. 4 (8): 1678—1692. PMID 17712814. doi:10.1002/cbdv.200790147. 
  9. Zuardi, A.W; J.A.S. Crippa; et al. (2006). „Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug” (PDF). Brazilian Journal of Medical and Biological Research. 39 (4): 421—429. PMID 16612464. doi:10.1590/S0100-879X2006000400001. 
  10. Consroe, P.; Sandyk, R.; Snider, S. R. (1986). „Open label evaluation of cannabidiol in dystonic movement disorders”. The International journal of neuroscience. 30 (4): 277—282. PMID 3793381. doi:10.3109/00207458608985678. 
  11. Snider, Stuart R.; Consroe, Paul (1985). „Beneficial and Adverse Effects of Cannabidiol in a Parkinson Patient with Sinemet-Induced Dystonic Dyskinesia”. Neurology (Suppl 1): 201. 

Spoljašnje veze[уреди]

  • Erowid Compounds found in Cannabis sativa